scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1008745269 |
P356 | DOI | 10.1023/A:1011987206008 |
P698 | PubMed publication ID | 11688963 |
P50 | author | Michal Šmahel | Q40512203 |
P2093 | author name string | Jandlová T | |
Símová J | |||
Vonka V | |||
Mendoza L | |||
Mikysková R | |||
Bubenik J | |||
P2860 | cites work | High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993 | Q29619885 |
Genetically engineered dendritic cell-based cancer vaccines (review). | Q34141341 | ||
Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens | Q34291693 | ||
The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses | Q34468846 | ||
High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update | Q34507305 | ||
Metastatic MHC class I-negative mouse cells derived by transformation with human papillomavirus type 16 | Q36622535 | ||
Solubilized tumour-associated antigens of methyl-cholanthrene-induced mouse sarcomas. Comparative studies by in vitro sensitization of lymph-node cells, macrophage electrophoretic mobility assay and transplantation tests | Q39479336 | ||
T cell growth factor: parameters of production and a quantitative microassay for activity | Q40680131 | ||
Vaccination for treatment of tumors: a critical comment | Q40921666 | ||
Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules | Q41120866 | ||
Cytokine gene-modified vaccines in the therapy of cancer | Q41151865 | ||
Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. | Q41503342 | ||
Antitumor and antimetastatic activity of interleukin 12 against murine tumors | Q41906195 | ||
Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV 16. | Q45856436 | ||
Gene transfer for immunotherapy of cancer | Q45879866 | ||
Inhibition of experimental lung metastasis of murine colon carcinoma cells depends on the amount of interleukin-2 secreted from the transduced cells. | Q48005880 | ||
In situ cytokine therapy: redistribution of clonally expanded T cells | Q56999983 | ||
Adhesion mediated by LFA-1 is required for efficient IL-12-induced NK and NKT cell cytotoxicity | Q57185273 | ||
Influence of the administration schedule on the therapeutic effect of interleukin-2 | Q68817133 | ||
Local and systemic effects during interleukin-2 therapy of mouse mammary tumors | Q68824500 | ||
Tumour inhibitory effects of TCGF/IL-2/-containing preparations | Q69866226 | ||
Liver NK1.1+ CD4+ alpha beta T cells activated by IL-12 as a major effector in inhibition of experimental tumor metastasis | Q71049413 | ||
Interleukin-12 induces cytotoxic NK1+ alpha beta T cells in the lungs of euthymic and athymic mice | Q71257944 | ||
Administration of recombinant interleukin 12 prevents outgrowth of tumor cells metastasizing spontaneously to lung and lymph nodes | Q72050072 | ||
Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production | Q72686394 | ||
Interleukin-12 activates NK cells for IFN-gamma-dependent and NKT cells for IFN-gamma-independent antimetastatic activity | Q73243204 | ||
Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma | Q73715471 | ||
Impact of the number of treatment courses on the clinical response of patients who receive high-dose bolus interleukin-2 | Q73719699 | ||
Genetically modified tumour vaccines | Q84009352 | ||
P433 | issue | 7 | |
P304 | page(s) | 581-587 | |
P577 | publication date | 2000-01-01 | |
P1433 | published in | Clinical & Experimental Metastasis | Q13470030 |
P1476 | title | Local cytokine treatment of HPV16-associated tumours results in inhibition of their lung metastases | |
P478 | volume | 18 |
Q42834024 | Modified HPV16 E7/HSP70 DNA vaccine with high safety and enhanced cellular immunity represses murine lung metastatic tumors with downregulated expression of MHC class I molecules | cites work | P2860 |
Search more.